Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

Publisher Name :
Date: 22-Jan-2013
No. of pages: 60

GBI Research, the leading business intelligence provider, has released its latest research, "Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share", which provides insights into the global statins market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the global statins market for dyslipidemia. The report gives insights into the share of generics in the global statins market for the years 2011 and 2018. The report examines the dyslipidemia treatment usage patterns in the US, the top five countries of Europe (The UK, France, Germany, Spain and Italy), and Japan. In addition to the global market landscape for statins, the report also provides details of the geographical distribution of statins sales in the major markets, including the US, the top five countries of Europe, and Japan. The report also includes insights into the statins R&D product pipeline, and explores the competitive landscape, including major players in the statins market. Finally, the report also includes analysis on mergers and acquisitions (M&A) and licensing and co-development deals that have taken place in the statins market.

Statins have dominated the global dyslipidemia therapeutics market for the last few decades. The National Cholesterol Education Program (NECP) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines have recommended the use of statins as the first choice of pharmacotherapy for the treatment of dyslipidemia. The global statins market, valued at $20.5 billion in 2011, is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 7.2% over the next seven years, to reach $12.2 billion by 2018. The highly consolidated statins market is expected to become increasingly competitive in the forecast period, with the patent expiries of (atorvastatin calcium), Vytorin (Ezetimibe/simvastatin), Lescol (fluvastatin) and Crestor (rosuvastatin), followed by severe generic erosion. GBI Research estimates that the generic sector in the global statins market will grow significantly in the future and will pose tough competition to new molecules.

Scope


  • Data and analysis on the statins market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.

  • Annualized market data for the statins market from 2004 to 2011, with forecasts to 2018.

  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment-seeking population, diagnosis population and prescription population.

  • Share of generics in the global statins market.

  • Key drivers and restraints that have had a significant impact on the global statins market.

  • The competitive landscape of the global statins market, including top companies benchmarking. The key companies studied in this report are Pfizer, AstraZeneca, Merck and Novartis.

  • Key M&A activities and licensing agreements that took place in the statins market.


Reasons to buy


  • Align their product portfolio to the markets with high growth potential

  • Build effective strategies to launch their pipeline products by identifying potential geographies

  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps

  • Develop key strategic initiatives by studying the key strategies of top competitors

  • Devise more tailored country-specific strategies through the understanding of key drivers and barriers and the market potential of each indication for different territories

  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth

  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious

Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Statins Market to 2018 - Introduction 8

3 Statins Market to 2018 - Global Statins Market 9
3.1 Introduction 9
3.2 Global Market Forecast 10
3.2.1 Branded and Generic Market Share 12
3.3 Annual Cost of Treatment 13
3.4 Treatment Usage Patterns 14
3.4.1 Disease Population 15
3.4.2 Treatment Seeking Population 15
3.4.3 Diagnosed Population 15
3.4.4 Prescription Population 15
3.5 Drivers and Restraints to the Statins Market 16
3.5.1 Drivers to the Statins Market 16
3.5.2 Restraints to the Statins Market 17
3.6 Major Marketed Products 19
3.6.1 Crestor (rosuvastatin calcium) 19
3.6.2 Lipitor (atorvastatin calcium) 20
3.6.3 Vytorin (ezetimibe/simvastatin) 21
3.6.4 Zocor (simvastatin) 22
3.6.5 Livalo (pitavastatin calcium) 22
3.6.6 Lescol XL (fluvastatin sodium) 23
3.6.7 Pravachol (pravastatin sodium) 24

4 Statins Market to 2018 - Statins Market in the US 25
4.1 Market 25
4.2 Annual Cost of Therapy (ACT) 27
4.3 Treatment Usage Pattern 28
4.3.1 Diseased Population 29
4.3.2 Treatment Seeking Population 29
4.3.3 Diagnosed Population 29
4.3.4 Patients on Statins Therapy 29

5 Statins Market to 2018 - Statins Market in the Top Five Countries of Europe 30
5.1 Market 30
5.2 Annual Cost of Therapy 33
5.3 Treatment Usage Pattern 34
5.3.1 Diseased Population 35
5.3.2 Treatment Seeking Population 35
5.3.3 Diagnosed Population 35
5.3.4 Patients on Statins Therapy 35

6 Statins Market to 2018 - Statins Market in Japan 36
6.1 Market 36
6.2 Annual Cost of Therapy 38
6.3 Treatment Usage Pattern 40
6.3.1 Diseased Population 41
6.3.2 Treatment Seeking Population 41
6.3.3 Diagnosed Population 41
6.3.4 Patients on Statins Therapy 41

7 Statins Market to 2018 - Product Pipeline Anlaysis 42
7.1 Introduction 42
7.2 Pipeline Analysis 42

8 Statins Market to 2018 - Competitive Landscape 43
8.1 Pfizer Inc. 44
8.1.1 Company Overview 44
8.1.2 SWOT Analysis 44
8.2 AstraZeneca PLC (AstraZeneca) 45
8.2.1 Company Overview 45
8.2.2 SWOT Analysis 45
8.3 Merck & Co Inc 46
8.3.1 Company Overview 46
8.3.2 SWOT Analysis 46
8.4 Novartis AG (Novartis) 47
8.4.1 Company Overview 47
8.4.2 SWOT Analysis 47

9 Statins Market to 2018 - Strategic Consolidation 48
9.1 Merger and Acquisition (M&A) Deals 48
9.2 Licensing Deals 49
9.2.1 Licensing Deals by Geography 49
9.3 Co-development Deals 51

10 Statins Market to 2018 - Appendix 52
10.1 Market Definitions 52
10.2 Abbreviations 52
10.3 Bibliography 55
10.4 Research Methodology 56
10.4.1 Coverage 56
10.4.2 Secondary Research 56
10.4.3 Primary Research 57
10.4.4 Therapeutic Landscape 57
10.4.5 Geographical Landscape 60
10.4.6 Pipeline Analysis 60
10.4.7 Competitive Landscape 60
10.5 Expert Panel Validation 60
10.6 Contact Us 60
10.7 Disclaimer 60

 List of Tables

Table 1: Statins Market, Global, Revenue ($bn), 2004-2011 10
Table 2: Statins Market, Global, Revenue Forecast ($bn), 2011 -2018 10
Table 3: Statins Market, Global, ACT ($), 2004-2011 13
Table 4: Statins Market, Global, ACT ($), 2011-2018 13
Table 5: Statins Market, Global, Treatment Usage Patterns (million), 2004-2011 14
Table 6: Statins Market, Global, Treatment Usage Patterns (million), 2011-2018 14
Table 7: Statins Market, the US, Revenue ($bn), 2004-2011 25
Table 8: Statins Market, the US, Revenue Forecast ($bn), 2011-2018 25
Table 9: Statins Market, the US, ACT ($), 2004-2011 27
Table 10: Statins Market, the US, ACT ($), 2011-2018 27
Table 11: Statins Market, the US, Treatment Usage Pattern (million), 2004-2011 28
Table 12: Statins Market, the US, Treatment Usage Pattern (million), 2011-2018 28
Table 13: Statins Market, Top Five Countries of Europe, Revenue ($bn), 2004-2011 31
Table 14: Statins Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2011-2018 31
Table 15: Statins Market, Top Five Countries of Europe, ACT ($), 2004-2011 33
Table 16: Statins Market, Top Five Countries of Europe, ACT ($), 2011-2018 33
Table 17: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004-2011 34
Table 18: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2011-2018 34
Table 19: Statins Market, Japan, Revenue ($bn), 2004-2011 36
Table 20: Statins Market, Japan, Revenue Forecast ($bn), 2011-2018 36
Table 21: Statins Market, Japan, ACT ($), 2004-2011 38
Table 22: Statins Market, Japan, ACT ($), 2011-2018 38
Table 23: Statins Market, Japan, Treatment Usage Pattern (million), 2004-2011 40
Table 24: Statins Market, Japan, Treatment Usage Pattern (million), 2011-2018 40
Table 25: Statins Market, Global, Product Pipeline, 2012 42
Table 26: Statins Market, M&A Deals ($m), 2008-2011 48
Table 27: Statins Market, Licensing Deals, 2005-2011 49
Table 28: Statins Market, Co-Development Deals, 2005-2008 51

 List of Figures

Figure 1: Statins Market, Global, Revenue ($bn), 2004-2018 10
Figure 2: Statins Market, Global, Generic and Branded Market Share (%), 2011 and 2018 12
Figure 3: Statins Market, Global, ACT ($), 2004-2018 13
Figure 4: Statins Market, Global, Treatment Usage Patterns (million), 2004-2018 14
Figure 5: Statins Market, Global, Drivers and Barriers, 2011 16
Figure 6: Statins Market, the US, Revenue ($bn), 2004 -2018 25
Figure 7: Statins Market, the US, ACT ($), 2004-2018 27
Figure 8: Statins Market, the US, Treatment Usage Pattern (million), 2004-2018 28
Figure 9: Statins Market, Top Five Countries of Europe, Revenue ($bn), 2004-2018 31
Figure 10: Statins Market, Top Five Countries of Europe, ACT ($), 2004-2018 33
Figure 11: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004-2018 34
Figure 12: Statins Market, Japan, Revenue ($bn), 2004-2018 36
Figure 13: Statins Market, Japan, ACT ($), 2004-2018 38
Figure 14: Statins Market, Japan, Treatment Usage Pattern (million), 2004-2018 40
Figure 15: Statins Market, Global, Top Companies' Market Share (%), 2011 43
Figure 16: Statins Market, Pfizer Inc., SWOT Analysis, 2011 44
Figure 17: Statins Market, AstraZeneca, SWOT Analysis, 2011 45
Figure 18: Statins Market, Merck & Co. Inc., SWOT Analysis, 2011 46
Figure 19: Statins Market, Novartis, SWOT Analysis, 2011 47
Figure 20: Statins Market, Strategic Consolidation, 2005-2011 48
Figure 21: GBI Research Market Forecasting Model 59

  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Siemens Adds To the Growth of Wind Power Generation Market
    Siemens has been presenting ground-breaking strategies and pioneering solutions for energy generation for an intelligent power supply globally. With an expansive portfolio and wide-ranging proficiency in wind power generation, Siemens is likely to aid in increasing the share of wind power in the US energy mix. With New Mexico’s vicinity to significant wind energy areas, [...]
  • Global Public Safety LTE Ecosystem Overview
    In view of its flourishing ecosystem, spectrum flexibility and performance metrics, LTE has emerged as the leading candidate for public safety mobile broadband networks. Public safety organizations and establishments have already begun planning to advance their networks to LTE-based public safety solutions. LTE provisions a varied range of services, from high bandwidth data services to [...]
  • RnR Market Research: Biochips Market Insights
    Growing R&D investment and subcontracting of pharmaceutical companies would lead to growth in biochips market in Asia along with an increase in the application of biochips products is estimated to improve opportunity for the global biochip market. Conversely, the high cost involved in manufacturing of biochips can be seen as a challenge for the same. [...]
  • Acute Rheumatic Carditis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Acute Rheumatic Carditis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Acute Rheumatic Carditis Report is to understand the market and pipeline status of the drugs around the Acute Rheumatic Carditis to explore the generic development opportunit......
  • Angina (Angina Pectoris)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Angina (Angina Pectoris)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Angina (Angina Pectoris) Report is to understand the market and pipeline status of the drugs around the Angina (Angina Pectoris) to explore the generic development opportunit......
  • 2016 Ranolazine Industry Market Report
    Published: 17-Aug-2016        Price: US 2800 Onwards        Pages: 150
    The 'Global and Chinese Ranolazine Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Ranolazine industry with a focus on the Chinese market. The report provides key statistics on the market status of the Ranolazine manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report provides a basic overview of the industry including its definition, applicati......
  • United States Atorvastatin Calcium Industry 2016 Market Research Report
    Published: 16-Aug-2016        Price: US 3800 Onwards        Pages: 131
    The United States Atorvastatin Calcium Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Atorvastatin Calcium industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Atorvastatin Calcium market analysis is provided for the United States markets including development trends, competitive landscape analysis, and key regions development stat......
  • United States Hypercholesterolemia Drug Market Report 2021
    Published: 15-Aug-2016        Price: US 3800 Onwards        Pages: 104
    Notes: Sales, means the sales volume of Hypercholesterolemia Drug Revenue, means the sales value of Hypercholesterolemia Drug This report studies sales (consumption) of Hypercholesterolemia Drug in USA market, focuses on the top players, with sales, price, revenue and market share for each player, covering - AbbVie - Aegerion Pharmaceuticals - AstraZeneca - Merck - Pfizer - Sanofi - Eli Lilly - GlaxoSmithKline......
  • Global Atorvastatin Calcium Market Research Report 2021
    Published: 05-Aug-2016        Price: US 2900 Onwards        Pages: 101
    Notes: Production, means the output of Atorvastatin Calcium Revenue, means the sales value of Atorvastatin Calcium This report studies Atorvastatin Calcium in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering Pfizer DSM Sinochem Pharmaceuticals Cadila Pharmaceuticals......
  • Global Rosuvastatin Calcium Sales Market Report 2020
    Published: 05-Aug-2016        Price: US 4000 Onwards        Pages: 129
    This report studies sales (consumption) of Rosuvastatin Calcium in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Roche Pharma Msn Laboratories Lunan Simcere Jingxin Pharm Hisun ZDTQ Jingda Pharm CSPCOE Runz......
  • Global Hypercholesterolemia Drug Market Research Report 2021
    Published: 04-Aug-2016        Price: US 2900 Onwards        Pages: 100
    Notes: Sales, means the sales volume of Hypercholesterolemia Drug Revenue, means the sales value of Hypercholesterolemia Drug This report studies Hypercholesterolemia Drug in Global market, especially in North America, Europe, China, Japan, India and Southeast Asia, focuses on top manufacturers in global market, with sales, price, revenue and market share for each manufacturer, covering - AbbVie - Aegerion Pharmaceuticals - AstraZeneca - M......
  • Global and China Simvastatin Sales Market Report to 2020
    Published: 26-Jul-2016        Price: US 2900 Onwards        Pages: 117
    This report studies Simvastatin in Global and China market, focuses on top manufacturers in global and China market, involving Simvastatin price of each type, production, revenue and market share for each manufacturer. This report also displays the production, revenue and market share of Simvastatin in USA, EU, China, Japan, India and Southeast Asia, forecast to 2020, from 2011. Split by product types, with production, revenue, market share and price of each type, as well as the t......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs